13.63
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché RDY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$13.52
Aprire:
$13.7
Volume 24 ore:
1.60M
Relative Volume:
0.65
Capitalizzazione di mercato:
$11.35B
Reddito:
$3.97B
Utile/perdita netta:
$644.90M
Rapporto P/E:
17.49
EPS:
0.7794
Flusso di cassa netto:
$90.19M
1 W Prestazione:
+0.22%
1M Prestazione:
-0.73%
6M Prestazione:
-2.99%
1 anno Prestazione:
-7.59%
Dr Reddys Laboratories Ltd Adr Stock (RDY) Company Profile
Compare RDY vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
RDY
Dr Reddys Laboratories Ltd Adr
|
13.63 | 11.26B | 3.97B | 644.90M | 90.19M | 0.7794 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.96 | 51.03B | 29.91B | 1.30B | 3.49B | 0.4056 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.32 | 40.20B | 17.53B | 1.58B | 444.18M | 1.3457 |
|
HLN
Haleon Plc Adr
|
9.06 | 40.78B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
ZTS
Zoetis Inc
|
77.69 | 32.81B | 9.51B | 2.64B | 2.14B | 6.0361 |
|
UTHR
United Therapeutics Corp
|
556.82 | 23.86B | 3.17B | 1.29B | 1.01B | 27.09 |
Dr Reddys Laboratories Ltd Adr Stock (RDY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-23 | Downgrade | Goldman | Neutral → Sell |
| 2025-06-05 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-12-19 | Downgrade | Nomura | Buy → Neutral |
| 2024-01-11 | Downgrade | Jefferies | Buy → Underperform |
| 2023-08-29 | Downgrade | HSBC Securities | Buy → Hold |
| 2023-05-18 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-03-17 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-30 | Iniziato | JP Morgan | Underweight |
| 2022-11-14 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-01-03 | Ripresa | BofA Securities | Neutral |
| 2021-07-27 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-02-02 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2020-09-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-09-18 | Aggiornamento | Investec | Sell → Hold |
| 2020-01-28 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-27 | Downgrade | CLSA | Buy → Outperform |
| 2020-01-09 | Aggiornamento | Citigroup | Sell → Buy |
| 2019-11-04 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-09-04 | Aggiornamento | Credit Suisse | Underperform → Outperform |
| 2019-07-01 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2019-06-20 | Iniziato | Deutsche Bank | Hold |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-02-19 | Aggiornamento | CLSA | Outperform → Buy |
| 2019-01-17 | Downgrade | Citigroup | Neutral → Sell |
| 2017-09-21 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-08-31 | Aggiornamento | CLSA | Underperform → Outperform |
| 2017-07-28 | Downgrade | CLSA | Underperform → Sell |
| 2016-07-27 | Downgrade | HSBC Securities | Hold → Reduce |
| 2016-07-27 | Downgrade | Jefferies | Hold → Underperform |
| 2016-02-10 | Aggiornamento | Credit Agricole | Underperform → Buy |
| 2015-11-10 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Dr Reddys Laboratories Ltd Adr Borsa (RDY) Ultime notizie
Dr. Reddy's Laboratories Ltd ADR (RDY-N) Stock Price and News - The Globe and Mail
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations - Investing.com UK
Earnings call transcript: Dr. Reddy’s Q4 2026 misses earnings expectations By Investing.com - Investing.com India
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push - Sahm
Dr. Reddy's Laboratories Ltd stock (INE089A01023): earnings miss and dual-market focus draw attentio - AD HOC NEWS
Dr. Reddy's Laboratories stock: Earnings miss shapes outlook - AD HOC NEWS
Dr. Reddy’s Labs ADR earnings missed by $0.05, revenue fell short of estimates - Investing.com India
Dr. Reddy's Earnings: Lenalidomide's Slide Digs Into Numbers, but Base Business Remains Solid - Morningstar
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast - Investing.com
Earnings call transcript: Dr. Reddy’s Q4 2026 revenue misses forecast By Investing.com - Investing.com Australia
Dr. Reddy's Laboratories Ltd stock (INE089A01023): Board meeting set for Q4 FY26 results - AD HOC NEWS
Dr. Reddy’s (NYSE: RDY) approves new ESOP and ADR stock option grants - Stock Titan
Dr. Reddy's Grants Employee Stock Options, Raising Dilution Concerns - Whalesbook
Dr. Reddy’s Laboratories grants over 1.19 million stock options to employees - Business Upturn
RDY Stock Price, Quote & Chart | DR. REDDY'S LABORATORIES-ADR (NYSE:RDY) - ChartMill
Dr. Reddy's Laboratories Ltd. Sponsored ADR Trade Ideas — LS:659157 - TradingView
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada - ChartMill
Earnings BeforeStock ScreenerSnapshot - Finviz
Dr. Reddy's on Pace for Largest Percent Increase Since June 2025 — Data Talk - Morningstar
Dr. Reddy's Labs (ADR) stock (US2565981035): Why Google Discover changes matter more now - AD HOC NEWS
GDR, ADR & IDR Companies Stock Prices | IIFL Capital - India Infoline
5 Indian ADRs crash up to 14% amid rising India-Pakistan military conflict - MSN
Dr Reddy’s (NYSE: RDY) Europe head reports 8,450 ADR-backed shares - Stock Titan
Dr. Reddy’s (NYSE: RDY) North America CEO reports 47,325 ADR shares - Stock Titan
ExxonMobil Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 3,675 Equity Shares Under Employee Stock Option Plan - scanx.trade
Employee stock options add 3,675 Dr. Reddy’s (NYSE: RDY) shares - Stock Titan
Morgan Stanley Upgraded, Tyson Foods Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply - Benzinga
Dr. Reddy's Laboratories Ltd Stock Faces Analyst Downgrade Despite Strong Valuation—What European - AD HOC NEWS
Sapient Quality Select ETF Holdings - Quiver Quantitative
Dr. Reddy’s Allots New ESOP Shares, Slightly Increases Equity Capital - TipRanks
Dr. Reddy’s (NYSE: RDY) allots 10,275 ESOP shares to employees - Stock Titan
Dr. Reddy's Laboratories Announces Special Window for Physical Share Transfer Re-lodgement - scanx.trade
Dr. Reddy's Laboratories Allots 10,275 Equity Shares Under Employee Stock Options Scheme - scanx.trade
Dr. Reddy’s Laboratories issues 10,275 equity shares under stock options scheme - Business Upturn
Dr Reddy's ADR Slumps 10% After Bid To Launch Weight-Loss Drug In Canada Hits Regulatory Hurdle - MSN
Mercurity Fintech Holding Inc ADR share price - Mint
Mitsubishi UFJ Financial Group Inc ADR share price - Mint
3 Generic Drug Stocks to Watch Despite Industry Headwinds - The Globe and Mail
DR. Reddy's Laboratories (NYSE:RDY) Fits the Peter Lynch GARP Investment Strategy - ChartMill
Dr. Reddy's Laboratories Receives SEC Letter Concluding Investigation Without Enforcement Action - scanx.trade
Dr. Reddy’s Stock Pops on US Launch Momentum: Buy the Breakout? - AD HOC NEWS
Toll Brothers Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dr. Reddy's Laboratories Allots 12,665 Equity Shares Under Employee Stock Option Schemes - scanx.trade
Dr. Reddy’s Allots 12,665 ESOP Shares, Nudging Up Equity Capital - TipRanks
Dr. Reddy's Laboratories (NYSE:RDY) Passes Key Peter Lynch GARP Investment Test - ChartMill
Dr Reddys Laboratories Ltd Adr Azioni (RDY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):